Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary by Florian, Jeffry, Sun, Qin, Schrieber, Sarah J., White, Richard, Shubow, Sophie, Johnson‐Williams, Bernadette E., Sheikhy, Morasa, Harrison, Nicholas R., Parker, Valerie J., Wang, Yow‐Ming, Strauss, David G.

Get full text

Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – (II) A Randomized Trial with IL‐5 Antagonists by Gershuny, Victoria, Sun, Qin, Schrieber, Sarah J., Matta, Murali K., Weaver, James L., Ji, Ping, Sheikhy, Morasa, Hsiao, Cheng‐Hui, Vegesna, Giri, Shah, Aanchal, Prentice, Kristin, Deering, Jennifer, Wang, Yow‐Ming, Strauss, David G., Florian, Jeffry

Get full text

Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – (I) A Randomized Trial with PCSK9 Inhibitors by Sheikhy, Morasa, Schrieber, Sarah J., Sun, Qin, Gershuny, Victoria, Matta, Murali K., Bai, Jane P.F., Du, Xiulian, Vegesna, Giri, Shah, Aanchal, Prentice, Kristin, Nalepinski, Colleen, Zineh, Issam, Wang, Yow‐Ming, Strauss, David G., Florian, Jeffry

Get full text

Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development – (III) A Randomized Trial with Interferon Beta‐1a Products by Florian, Jeffry, Gershuny, Victoria, Sun, Qin, Schrieber, Sarah J., Matta, Murali K., Hazel, Anthony, Sheikhy, Morasa, Weaver, James L., Hyland, Paula L., Hsiao, Cheng‐Hui, Vegesna, Giri, DePalma, Ryan, Shah, Aanchal, Prentice, Kristin, Sanabria, Carlos, Wang, Yow‐Ming, Strauss, David G.

Get full text